Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications

British Journal of Surgery

Volumn 98, Issue 12, 2011, Pages 1735-1741

  Hirao, M ^a   Ando, N ^c   Tsujinaka, T ^a   Udagawa, H ^d   Yano, M ^b   Yamana, H ^g   Nagai, K ^e   Mizusawa, J ^f   Nakamura, K ^f  

^a OSAKA NATIONAL HOSPITAL   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c TOKYO DENTAL COLLEGE   (Japan)

^d TORANOMON HOSPITAL   (Japan)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^f NATIONAL CANCER CENTER   (Japan)

^g KURUME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; FEMALE; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SQUAMOUS CELL CARCINOMA; THORACOTOMY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; INTRAOPERATIVE COMPLICATIONS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; RISK FACTORS; THORACOTOMY; TREATMENT OUTCOME;

EID: 84856462953     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.7683     Document Type: Article

References (15)

1. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy on oesophageal carcinoma: A meta-analysis. Lancet Oncol 2007; 8: 226-234. (Pubitemid 46291702)
2. Thirion P, Michiels S, Le Maitre A, Tierney J; Group MoCiECC. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma. J Clin Oncol 2007; 25(Suppl): Abstract 4512.
3. Igaki H, Ando N, Shinoda M, Shimizu H, Nakamura T, Ozawa S et al. A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907). J Clin Oncol 2008; 26(Suppl): Abstract 4510.
4. Ruol A, Portale G, Castoro C, Merigliano S, Cagol M, Cavallin F et al. Effects of neoadjuvant therapy on perioperative morbidity in elderly patients undergoing esophagectomy for esophageal cancer. Ann Surg Oncol 2007; 14: 3243-3250. (Pubitemid 47594270)
5. Medical Research Council Oesophageal CancerWorking Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 2002; 359: 1727-1733.
6. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG et al. Long-term results of RTOG trial 8911 (USA intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007; 25: 3719-3725. (Pubitemid 47372613)
7. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl JMed 1998; 339: 1979-1984. (Pubitemid 29024130)
8. Sobin LH, Wittekind C (eds). TNM Classification ofMalignant Tumors (UICC) (6th edn).Wiley-Liss: New York, 2002.
9. Japanese Society for Esophageal Diseases. Guideline for clinical and pathological studies on carcinoma of the esophagus (9th edn). Esophagus 2004; 1: 61-88.
10. National Cancer Institute. Common Toxicity Criteria (CTC), version 2.0 (updated 1999). http://ctep.cancer.gov/ protocolDevelopment/electronic- applications/ ctc.htm [accessed 10 August 2011].
11. Schlag PM. Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg 1992; 127: 1446-1450.
12. Wang HW, Kuo KT,Wu YC, Huang BS, Hsu WH, Huang MH et al. Surgical results of upper thoracic esophageal carcinoma. J Chin Med Assoc 2004; 67: 447-457.
13. Igaki H, Kato H, Tachimori Y, Nakanishi Y, Shimoda T. Surgery for clinical T3 carcinomas of the upper thoracic oesophagus and the need for new strategies. Br J Surg 2005; 92: 1235-1240. (Pubitemid 41475233)
14. Kunisaki C, Makino H, Otsuka Y, Kojima Y, Takagawa R, Kosaka T et al. Appropriate routes of reconstruction following transthoracic esophagectomy. Hepatogastroenterology 2007; 54: 1997-2002.
15. Kunisaki C, Makino H, Akiyama H, Nomura M, Otsuka Y, Ono HA et al. Predictive factors for anastomotic leakage in the neck after retrosternal reconstruction for esophageal cancer. Hepatogastroenterology 2008; 55: 98-102. (Pubitemid 351462170)